Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568709 · ClinicalTrials.gov registry record · Early Phase 1
Oxytocin MEG Study
A Early Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
NCT02568709: Completed Early Phase 1 study, sponsored by University of California, San Francisco.
NCT02568709 is a Early Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 40 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02568709, a Early Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The specific aim of this proposal is to investigate the neurophysiological mechanisms of oxytocin's (OT) prosocial effects in patients with schizophrenia and healthy subjects using magnetoencephalography. Hypothesis A: When OT is administered to patients with schizophrenia, fear-related amygdala hyperreactivity and fusiform gyrus (FG) and anterior cingulate cortex (ACC) hypoactivity will be normalized. Hypothesis B: When OT is administered to patients with schizophrenia, the decreased functional connectivity (FC) between the amygdala, FG, and ACC will be normalized. By elucidating the neurophysiological mechanisms of OT administration on emotional face processing, investigators will bee able to: 1. understand the pathophysiology of the functionally debilitating social cognitive deficits of schizophrenia, 2. test the efficacy of OT in normalizing the neural abnormalities underlying these social deficits, and 3. develop and optimize novel treatments for these currently untreatable deficits.
Primary Outcome
During tasks in which participants will see and hear various stimuli, investigators will measure the change in neural activity in the amygdala, the dorsal anterior cingulate cortex, as well as the fusiform gyrus using the MEG scanner.
Interventions
- DRUG Oxytocin
- DRUG Saline Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-12 |
| Phase | Early Phase 1 |
What the finished NCT02568709 record still lists
NCT02568709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which Oxytocin is the first listed.
NCT02568709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02568709 about?
NCT02568709 is a clinical study titled "Oxytocin MEG Study". The specific aim of this proposal is to investigate the neurophysiological mechanisms of oxytocin's (OT) prosocial effects in patients with schizophrenia and healthy subjects using magnetoencephalography. Hypothesis A: When OT is administered to patients with schizophrenia, fear-related amygdala hy...
What is the current status of trial NCT02568709?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2012-02. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02568709?
The interventions under investigation include: Oxytocin (DRUG), Saline Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT02568709?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02568709's enrollment target sits among peer trials
40 629th of 2000 higher than 1,312 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia